Figure 2.
Guidelines for use of replacement to treat CRS-associated hypofibrinogenemia or coagulopathy. Fibrinogen concentrate (A), cryoprecipitate (B). *Minor bleeding events include epistaxis, intramuscular bleeding, and menorrhagia. †From RiaSTAP Prescribing Information.13 ‡Major bleeding events include head trauma and intracranial hemorrhage. For patients without bleeding, fibrinogen levels should be monitored and maintained at >1.5 g/L. §Each unit of cryoprecipitate contains at least 150 mg fibrinogen per unit. Two units of cryoprecipitate per 10 kg body weight generally increases fibrinogen concentration by 1 g/L, except in cases of DIC or continued bleeding with massive transfusion.

Guidelines for use of replacement to treat CRS-associated hypofibrinogenemia or coagulopathy. Fibrinogen concentrate (A), cryoprecipitate (B). *Minor bleeding events include epistaxis, intramuscular bleeding, and menorrhagia. †From RiaSTAP Prescribing Information.13  ‡Major bleeding events include head trauma and intracranial hemorrhage. For patients without bleeding, fibrinogen levels should be monitored and maintained at >1.5 g/L. §Each unit of cryoprecipitate contains at least 150 mg fibrinogen per unit. Two units of cryoprecipitate per 10 kg body weight generally increases fibrinogen concentration by 1 g/L, except in cases of DIC or continued bleeding with massive transfusion.

Close Modal

or Create an Account

Close Modal
Close Modal